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(145.5~mot/t [88.0;465.0], 44.5mt/mn) and the 
end of the treatment (168.0~mot/t [66.0;363.0], 
39.8 mt/mn). 
Conclusion: This study showed treatment of pa- 
tients with LF had an exceLLent renal safety profile 
particuLarLy in patients either with a normal or 
altered renal function receiving combined nephro- 
toxic drugs. 
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Introduction: Severe sepsis, defined as a systemic 
response to infection with acute organ dysfunction, 
is associated with significant morbidity and mor- 
tality. Immunosuppression in hematologic patients 
resulting from chemotherapy Leads to severe infec- 
tion, which is a frequent cause of death. However, 
there is a paucity of data regarding the epidemi- 
otogy of severe sepsis in hematology malignancies. 
We conducted a study to determine estimates of 
the incidence and mortality of sepsis in this popu- 
Lation. 
Methods: ALL adult patients with hematologic 
malignancies admitted in our institution were 
prospectively observed. We analyzed the data of 
aLL episodes of sepsis which occurred during 4-year 
period including the foLLowing parameters: type of 
hematologic malignancy, chemotherapy regimens 
and setting, neutropenia duration, cLinicaL and mi- 
crobioLogicaL documentation and mortality. Sep- 
sis was defined according to the American CoL- 
Lege of Chest Physicians/Society of Critical Care 
Medicine. 
Results: Between January 2002 and September 
2005, from a total of 237 patients foLLowed, 
85 episodes of sepsis occurred in 68 (28%) patients. 
In these patients the type of underlying disease 
were: acute myetocytic Leukemia in 20 (29%), tym- 
phoma in 19 (28%), Leukemia acute Lymphocytic 
Leukemia in 8 (12%), chronic myetocytic Leukemia 
in 8 (12%), Hodgkin's disease in 6 (9%), myetoma 
in 3 (4%) and others 4 (6%).The median age in our 
population was 55 years. Among the patients with 
sepsis 21 (31%) had septicemia, 20 (29%) pneumo- 
nia, 16 (24%) both cLinicaL presentation, pneumonia 
plus septicemia and in 11 (16%) no infectious cause 
was found. Forty-one patients (60%) had a micro- 
bioLogicaLLy documented infection (MDI), 17 (25%) 
had only a cLinicaLLy documented infection (CDI) 
and 7 (10%) had fever of unknown origin (FUO). Of 
those patients with MDI, 35 cases (51%) had sep- 
ticemia, 6 (9%) had LocaLized infection without bac- 
teremia and 3 (5%) had a fungat MDI. The organism 
distribution was: Gram-negative baciLLi 21 (47%), 
Gram-positive 19 (43%), anaerobe 1 (4%) and fungus 
3 (6%). MortaLity from sepsis was 44% (30), of these, 
50% (15) were neutropenic when death occurred. 
The median age of the patients who died from 
sepsis was 49 years. 
Conclusions: We found that severe sepsis is a 
common and deadly complication in hematologic 
patients. The incidence and mortality in this pop- 
utation is not affected by age and is higher than 
was reported in the Literature. Advances in medical 
therapy and early diagnosis for these complicated 
patients could have a significant impact on cancer 
survivaL. 
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Background: Stenotrophomonas maltophilia (SM) 
is an emerging pathogen. We noticed in past years, 
increasing numbers of hematology patients with 
SM bacteremia in our hospitaL. Such patients are 
at high risk of SM infection but empiric antibiotic 
regimes often do not cover this muLti-resistant 
organism. 
ObJectives: We aim to characterize SM bacteremia 
in hematology patients; so as to identify those at 
risk of infection and modify practices to optimize 
care. 
Methods: Case notes of hematology patients with 
SM bacteremia between January 1999 and Decem- 
ber 2004 was reviewed retrospectively. CLinicaL 
characteristics, risk factors, manifestation of bac- 
teremia, and outcome were documented. 
Results: In the study period, SM bacteremia oc- 
curred in 36 hematology patients. Case notes 
were avaiLabLe for review in only 31 patients 
(20 males, 11 females; mean age 46 years). 
The most common hematoLogicaL disorder was 
acute myetoid Leukemia (67.7%). Other patients 
had tymphoma (9.7%), myetoma (3.2%), other 
Leukemia (12.9%) and aptastic anemia (3.2%). Mean 
Length of stay before bacteremia was 22 days. 
Five patients (I 6. I%) had bone marrow transplants, 
24 (77.4%) received chemotherapy; bacteremia 
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occurred 17.8 days after treatment. At[ but 1 
patient (93%) were neutropenic and neutropenia 
tasted 20.4 days before bacteremia. Twenty-six pa- 
tients (83.9%) had central venous catheters (CVC). 
At[ patients received antibiotics. Twenty-five pa- 
tients (80.6%) received carbapenems for a mean 
of 10.2 days (range 2-31 days) before onset of 
SM bacteremia. Almost at[ patients (93%) manifest 
infection with fever ranging from 37.6 to 40.2°C. 
Hypotension occurred in 5 patients (16.7%). Eigh- 
teen patients (58.1%) had symptoms related to: 
respiratory system (25.8%), skin (12.9%), CVC (6%) 
and gastrointestinal tract (16.1%); but SM was iso- 
lated only from the sputum of 4 patients and soft 
tissue of one. Complications were uncommon: 3 pa- 
tients (9.7%) had renal failure and 3 had respiratory 
compromise. The mean Apache-II score on day of 
bacteremia was 18.7. Twelve patients (38.7%) re- 
quired admission to ICU. CVC was removed in 13 pa- 
tients (41.9%). Twenty-four patients (77.4%) were 
treated with Bactrim and 2 (6.5%) had quino[ones. 
Five patients (16.1%) received inappropriate antibi- 
otics and at[ died. Mortality rate was 35.5% (11 
patients) but 3 deaths were deemed unrelated to 
SM infection. 
Conclusions: In hematology patients with pro- 
tonged hospitalization and neutropenia, SM bac- 
teremia should be considered when fever occurs 
despite broad-spectrum antibiotics. 
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Background: Therapy-related mye[osuppression is 
more common in older patients (pts) with DLBCL 
who are treated with regimens such as cyc[o- 
phosphamide, doxorubicin, vincMstine, prednisone 
(CHOP), with or without Mtuximab (R). FebM[e 
neutropenia (FN) may subsequently complicate the 
course of these patients. We examined the oc- 
currence of FN among a large series of older pts 
with DLBCL treated with either CHOP or R-CHOP 
on an onco[ogy intergroup tr ial  Risk factors for the 
occurrence of FN were identified among these pts. 
Objectives: To determine: (1) the incidence of FN 
in this pt population, and (2) risk factors that are 
predictive for the occurrence of FN in these pts. 
Methods: Pts >60 years of age with previously 
untreated DLBCL enrolled on a US onco[ogy coop- 
erative group trial (CALGB 9793/ECOG-SWOG 4494) 
were randomized to initial therapy with either 
(CHOP) or (R-CHOP). Data regarding the nadir neu- 
trophi[ counts and complications of FN were col- 
lected. The incidence of FN was ascertained, and 
baseline demographic features that were predic- 
tive for the occurrence of FN were identified. 
Results: Of the 632 pts enrolled on this trial, 
data was available for 520 pts with regard to 
nadir counts and the occurrence of FN. Among 
these 520 pts, 212 (41%) had at [east one episode 
of FN complicating their treatment course. Overall, 
FN occurred in 261/3216 cycles of therapy (8%). 
The median time to FN was Day 11, with 38% of 
at[ FN episodes occurring in cycle one of ther- 
apy. Of these 520 patients, 141 had at [east one 
hospitalization for FN, with a median period of 
hospitalization of five (range, 1-121) days. The 
occurrence of FN in cycle 1 of therapy was as- 
sessed by the study entry demographics, to identify 
risk factors for this complication. Analysis of only 
cycle 1 was undertaken in order to minimize the 
impact of dose reduction, dose delay, and mye[oid 
growth factor usage. Factors found to be predictive 
for cycle 1 FN included advancing age (evaluated as 
a continuous variable, p = 0.001), a tess favorable 
performance status (PS 2,3) (p=0.02), baseline 
hemoglobin of <12g/d[ (p= 0.0001), an elevated 
LDH (p=0.02), and a high-intermediate/high risk 
International Prognostic Index (IPI) score (p = 0.02). 
The presence of marrow involvement had no im- 
pact on the occurrence of FN. 
Conclusions: FN is a common occurrence among 
older pts with DLBCL receiving anthracyc[ine-based 
chemotherapy regimens. This complication tends 
to occur early in the treatment course. Risk fac- 
tors for the subsequent occurrence of FN include 
advancing age, poor PS, anemia, elevated LDH, and 
high-intermediate/high risk IPI score. Using these 
predictive factors, pt subgroups may be identified 
at baseline that wi[[ most benefit from mye[oid 
growth factor support with their therapy. 
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Introduction: Septicaemia due to unusual bacteria 
may be difficult to establish and often difficult to 
